Identification of microRNAs associated with glioma diagnosis and prognosis
Metrics: PDF 1277 views | HTML 1889 views | ?
Xinyun Ye1,*, Wenjin Wei1,*, Zhengyu Zhang1,*, Chunming He1, Ruijin Yang1, Jinshi Zhang1, Zhiwu Wu1, Qianliang Huang1, Qiuhua Jiang1
1Department of Neurosurgery, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi 341000, China
*These authors have contributed equally to this work
Qiuhua Jiang, email: firstname.lastname@example.org
Keywords: glioma, miRNA, diagnosis, prognosis, meta-analysis
Received: August 23, 2016 Accepted: December 15, 2016 Published: January 02, 2017
The sensitivity and specificity of microRNAs (miRNAs) for diagnosing glioma are controversial. We therefore performed a meta-analysis to systematically identify glioma-associated miRNAs. We initially screened five miRNA microarray datasets to evaluate the differential expression of miRNAs between glioma and normal tissues. We next compared the expression of the miRNAs in different organs and tissues to assess the sensitivity and specificity of the differentially expressed miRNAs in the diagnosis of glioma. Finally, pathway analysis was performed using GeneGO. We identified 27 candidate miRNAs associated with glioma initiation, progression, and patient prognosis. Sensitivity and specificity analysis indicated miR-15a, miR-16, miR-21, miR-23a, and miR-9 were up-regulated, while miR-124 was down-regulated in glioma. Ten signaling pathways showed the strongest association with glioma development and progression: the p53 pathway feedback loops 2, Interleukin signaling pathway, Toll receptor signaling pathway, Parkinson’s disease, Notch signaling pathway, Cadherin signaling pathway, Apoptosis signaling pathway, VEGF signaling pathway, Alzheimer disease-amyloid secretase pathway, and the FGF signaling pathway. Our results indicate that the integration of miRNA, gene, and protein expression data can yield valuable biomarkers for glioma diagnosis and treatment. Indeed, six of the miRNAs identified in this study may be useful diagnostic and prognostic biomarkers in glioma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.